{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=2", "query": { "intervention": "Abiraterone and Prednisone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 155, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T23:38:00.814Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04748042", "title": "Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Castrate Sensitive Prostate Cancer", "Oligometastatic Disease" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "External Beam Radiotherapy", "type": "RADIATION" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "2021-05-28", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04748042" }, { "nct_id": "NCT06212583", "title": "High-Risk Metachronous Oligometastatic Prostate Cancer Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Oligometastatic Disease" ], "interventions": [ { "name": "niraparib/abiraterone acetate", "type": "DRUG" }, { "name": "Stereotactic ablative radiation therapy (SABR)", "type": "RADIATION" }, { "name": "Androgen deprivation therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 88, "start_date": "2024-04-17", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06212583" }, { "nct_id": "NCT04691804", "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Fuzuloparib , Abiraterone acetate and Prednisone", "type": "DRUG" }, { "name": "Fuzuloparib Placebo， Abiraterone acetate and Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 496, "start_date": "2021-03-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 17, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691804" }, { "nct_id": "NCT03414034", "title": "Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cardiff Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2018-08-14", "completion_date": "2023-10-16", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414034" }, { "nct_id": "NCT01786265", "title": "Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Nilutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 310, "start_date": "2013-02-05", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786265" }, { "nct_id": "NCT02987543", "title": "Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 387, "start_date": "2017-02-06", "completion_date": "2023-02-15", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Duarte, California + 30 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02987543" }, { "nct_id": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Epithelial Ovarian Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "XL102", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-02-10", "completion_date": "2024-05-02", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04726332" }, { "nct_id": "NCT03827473", "title": "Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostatic Adenocarcinoma", "Stage IV Prostate Cancer", "Stage IVA Prostate Cancer", "Stage IVB Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1, "start_date": "2019-02-08", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-06-25", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03827473" }, { "nct_id": "NCT05818683", "title": "A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Neoplasms", "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "Pasritamig", "type": "DRUG" }, { "name": "Cetrelimab", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone acetate plus prednisone (AAP)", "type": "DRUG" }, { "name": "Lutetium Lu-177 vipivotide tetraxetan", "type": "DRUG" }, { "name": "JNJ-101556143", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 300, "start_date": "2023-04-26", "completion_date": "2028-05-23", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 7, "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05818683" }, { "nct_id": "NCT07005154", "title": "A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Hormone Sensitive Prostate Cancer" ], "interventions": [ { "name": "ASP5541", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" }, { "name": "Adrenocorticotropic hormone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 218, "start_date": "2025-08-19", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-06T23:38:00.814Z", "location_count": 12, "location_summary": "Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago Ridge", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07005154" } ] }